共 50 条
- [41] Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment DIABETES OBESITY & METABOLISM, 2018, 20 (12): : 2860 - 2868
- [47] Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety DIABETES OBESITY & METABOLISM, 2022, 24 (01): : 72 - 81
- [48] One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension DIABETES OBESITY & METABOLISM, 2015, 17 (09): : 835 - 842
- [49] A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes DIABETES OBESITY & METABOLISM, 2019, 21 (04): : 1001 - 1009
- [50] A pragmatic randomized clinical trial of insulin glargine 300 U/mLvs first-generation basal insulin analogues in insulin-naive adults with type 2 diabetes: 6-month outcomes of theACHIEVEControl study DIABETES OBESITY & METABOLISM, 2020, 22 (11): : 2004 - 2012